No registrations found.
ID
Source
Health condition
Neurotransmission and pharmacokinetics after cannabis administration
Sponsors and support
Intervention
Outcome measures
Primary outcome
Neurotransmission of glutamate, GABA and dopamine will be assessed using MRS and resting state fMRI.
Secondary outcome
THC kinetics in blood, subjective experiences of drug, and cognitive performance
Background summary
The current project studies brain markers that reflect neuroadaptations in occasional and chronic cannabis users.
Acute influences of cannabis on neurotransmission in the limbic system are assessed in a placebo-controlled study.
Study objective
The study will assess brain kinetics of glutamate, GABA and dopamine during the absorption and elimination phase of THC.
And relate THC kinetics in blood to brain kinetics of neurotransmission and subjective experiences of drug liking and wanting.
Study design
Measurments will take place at and after Tmax of THC
Intervention
300 microg/kg bodyweight THC and placebo
E.L. Theunissen
Maastricht
The Netherlands
0433881940
e.theunissen@maastrichtuniversity.nl
E.L. Theunissen
Maastricht
The Netherlands
0433881940
e.theunissen@maastrichtuniversity.nl
Inclusion criteria
Occasional users (N=20): Used cannabis between 1 times a month and 1 times a week during the previous year
Chronic users (N=20): Used cannabis more than 3 times a week during the previous year
• Age between 18 and 40 years
• Free from psychotropic medication
• Good physical health as determined by medical examination and laboratory analysis
• Absence of any major medical, endocrine and neurological condition
• Normal weight, body mass index (weight/height2) between 18 and 28 kg/m2
• Written Informed Consent
• Good knowledge and understanding of the Dutch language
Exclusion criteria
• History of drug abuse (other than the use of cannabis) or addiction (determined by the medical questionnaire, drug questionnaire and medical examination)
• Pregnancy or lactation
• Hypertension (diastolic> 90; systolic> 140)
• Current or history of psychiatric disorder (determined by the medical questionnaire and medical examination)
• Liver dysfunction
• (Serious) side effects to previous cannabis
• History of cardiac dysfunctions (arrhythmia, ischemic heart disease,…)
• For women: no use of a reliable contraceptive
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4692 |
| NTR-old | NTR4897 |
| Other | METC Azm/UM : METC 143037 |